BCG-Unresponsive NMIBC: Balancing Care and Financial Considerations

Author(s):

Mark D. Tyson, II, MD, MPH

A panelist discusses how treatment decisions for BCG-unresponsive non–muscle-invasive bladder cancer (NMIBC) involve careful consideration of patient preferences, long-term cost-effectiveness, and available financial assistance programs, balancing the higher upfront costs of newer therapies with their potential economic benefits from reduced recurrence rates and treatment frequency.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP: 1.Overview of BCG-Unresponsive NMIBC

EP: 2.Challenges of BCG-Unresponsive NMIBC

EP: 3.Standard Treatment Options for BCG-Unresponsive NMIBC

EP: 4.Unresponsive NMIBC: Gene Therapies

EP: 5.Gene Therapy Considerations for BCG-Unresponsive NMIBC

EP: 6.Gene Therapy Data for BCG-Unresponsive NMIBC

EP: 7.BCG-Unresponsive NMIBC: Insights for Newer Treatment Modalities

EP: 8.Addressing Challenges in BCG-Unresponsive NMIBC: Overview and Unmet Needs

EP: 9.Current Treatment Options for BCG-Unresponsive NMIBC

EP: 10.The Impact of Targeted Gene Therapy and Nadofaragene Firadenovec on BCG-Unresponsive NMIBC

EP: 11.Advancements in BCG-Unresponsive NMIBC and the Impact of Trial Results and Long-Term Follow-Up

EP: 12.Discussing Treatment Options for BCG-Unresponsive NMIBC

EP: 13.Cost-Effectiveness and Patient Support in Treating BCG-Unresponsive NMIBC

EP: 14.Reducing Resource Expenditure in Clinics with New Gene Therapies for BCG-Unresponsive NMIBC

EP: 15.Enhancing Access to BCG-Unresponsive NMIBC Treatments

EP: 16.Navigating BCG-Unresponsive NMIBC and Emerging Therapies

EP: 17.The Impact of Gene Therapy and Advancements in BCG-Unresponsive NMIBC Treatment

Now Viewing

EP: 18.BCG-Unresponsive NMIBC: Balancing Care and Financial Considerations

EP: 19.Navigating Treatment Choices and Financial Considerations in BCG-Unresponsive NMIBC

EP: 20.Adoption of New Treatments for BCG-Unresponsive NMIBC

EP: 21.Future Directions of BCG-Unresponsive NMIBC Management

What is your approach to discussing treatment options with patients, especially when considering the long-term financial impact of different therapies?
With all the available treatments on the market, what are your patient preferences when it comes to treatment experiences?
Annual cost analyses suggest that some newer therapies may have higher upfront costs but can be more economical in the long run due to fewer recurrences and less frequent administration.
How does the cost-effectiveness of treatments, particularly in relation to newer therapies, influence your recommendations for patients with BCG-unresponsive NMIBC?
Are there specific tools or resources you rely on to help assess and present these options to patients?
What financial assistance or patient support programs (eg, co-pay cards, patient assistance foundations, or programs) have you found most helpful in ensuring patients can afford and access the right treatments, and how do you guide patients in utilizing these resources?